Is AgeX Therapeutics, Inc. overvalued or undervalued?

As of 8 May 2025, the valuation grade for AgeX Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is currently considered overvalued, particularly given its price-to-book value of 31.10 and negative ratios such as EV to EBIT at -2.81 and EV to EBITDA at -2.84. The return on equity (ROE) is alarmingly low at -1036.68%, reflecting severe financial distress.
In comparison with its peers, AgeX Therapeutics shows a stark contrast; for instance, Regulus Therapeutics, Inc. has an EV to EBITDA of -9.7830, while ARCA biopharma, Inc. stands at -0.8008. These figures suggest that AgeX is not only underperforming but also lacks the financial stability seen in its competitors. The company's stock has underperformed against the S&P 500 over various time frames, with a one-year return of -30.83% compared to the index's 10.26%, reinforcing the notion of overvaluation.